Disease Domain | Count |
---|---|
Neoplasms | 6 |
Infectious Diseases | 5 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 6 |
Top 5 Target | Count |
---|---|
ROCK1(Rho-associated protein kinase 1) | 1 |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org. |
Originator Org.- |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date06 May 2024 |
Sponsor / Collaborator |
Start Date01 May 2024 |
Sponsor / Collaborator |
Start Date07 Mar 2024 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Chlorpromazine analogues 21 | Neoplasms More | Preclinical |
Chlorpromazine analogues 23 | Bacterial Infections More | Preclinical |
ROCK1 inhibitors(Medical University of Silesia) ( ROCK1 ) | Neoplasms More | Preclinical |
Chlorpromazine analogues 8 | Neoplasms More | Preclinical |
Chlorpromazine analogues 20 | Bacterial Infections More | Preclinical |